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Abstract
Background: There is evidence that postmenopausal women with rheumatoid arthritis (RA) on glucocorticoid (GC)
therapy and bisphosphonate (BP) have an increased risk for atypical subtrochanteric and atypical diaphyseal femoral
fracture (AFF). The underlying mechanism has not been elucidated so far. Using peripheral quantitative computed
tomography (pQCT), the aim of the present study was to compare bone geometry, volumetric bone mineral density
(vBMD) and bone strength of femoral shaft in BP-treated and BP-naïve postmenopausal women with RA.
Methods: Prospective cross-sectional pQCT scans were taken at 33 % of total femur of BP-treated and BP-naïve RA
patients. Bone parameters of the two groups were compared and correlated to disease characteristics and muscle
cross-sectional area (CSA).
Results: A total of 60 consecutive postmenopausal RA patients, 20 with BP therapy and 40 BP-naïve, were included in
the study. The median age of the subjects was 63.5 years (range 48–85 years), and median disease duration (RA) was
12.0 years (range 2–47 years). Height and weight of the patients of the two groups were comparable. Women in the
BP group were on average 4.3 years older (p = 0.044), and duration since menopause was on average 5.76 years longer
(p = 0.045). In the BP group, there was a 13.31 % reduced muscle cross-sectional area around the proximal thigh
(p = 0.013); cortical CSA was smaller by 5.3 % (p = 0.043); however, total and medullary CSA, as well as cortical
vBMD and the polar bone stress–strain index of the femoral shaft were similar in the two groups. In regression
analysis, age, time since menopause and muscular CSA were significant factors determining cortical CSA, cortical
thickness and femoral index (p < 0.05). Regression model showed no significant effect of BP therapy on bone
geometry and density of the femoral diaphysis at 33 %.
Conclusion: Differences in cortical CSA between BP-treated and BP-naïve postmenopausal RA patients were found to
be associated only with differences in age, time since menopause and muscle cross-sectional area around the proximal
thigh. In interpreting our results, it should be kept in mind that BP was given only to patients with increased fracture
risk. This fact might have a confounding effect on our findings of differences between the two groups.
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Background
In rheumatoid arthritis (RA), bone damage such as ero-
sions, juxta-articular osteopenia, as well as generalized
osteopenia and osteoporosis are well recognized [1].
Decreased cortical thickness and enlarged total cross-
sectional area have recently been described in the shaft
of the metacarpal bone, radius and tibia [2]. In order to
prevent further bone loss, antiresorptive therapies are
applied to patients with diagnosed osteoporosis or with
increased fracture risk. Whereas the effect of anti-
resorptives, particularly bisphosphonate (BP) on tra-
becular bone such as spine and femoral head is clearly
defined and its use leads to a prevention of peripheral
and vertebral fractures, the effect on bone shaft geom-
etry is subject to controversy. Potential complications
of long-term BP use, such as atypical femoral fracture
(AFF) of the diaphysis raise questions about the suit-
ability of its use over time, particularly in patients with
active RA with concomitant use of glucocorticoid (GC),
and low vitamin D levels [3]. Clinical data support a
BP-induced increased risk of AFF, as shown by a 70 %
reduction in AFF one year after BP withdrawal [4].
Peripheral quantitative computed tomography (pQCT)
is a three-dimensional measuring technique that allows
the assessment of cross-sectional bone geometry and
volumetric bone mineral density (vBMD). Because bone
shaft geometry mainly results from mechanical force,
aging, duration and therapy of RA [5–7] and therapy-
induced alterations in bone shaft geometry are challenging
to measure [8], pQCT is more advantageous compared to
2-dimensional methods such as dual x-ray absorptiometry
(DXA) that permit measurement of bone geometry only
in the projected plane and is dependent on bone rotation,
tissue and calcification [9]. So far, when pQCT was used
in investigations of RA patients, the bones assessed were
the tibia, the radius and the metacarpal bone [2, 10–14].
To date, no study has examined true volumetric BMD
and bone geometry of femoral bones in RA.
The aim of the present study was, therefore, to com-
pare bone properties measured at the femoral diaphysis
of RA patients treated with bisphosphonate with those
of RA patients who did not undergo such therapy.
Methods
We conducted a prospective cross-sectional study to
evaluate the effect of BP therapy on femoral bone geom-
etry, volumetric density and bone strength in a cohort of
postmenopausal RA patients treated with BP compared
to a BP-naïve control RA cohort. BP therapy was given
to patients with osteoporosis, increased fracture-risk or
as prevention of glucocorticoid-induced osteoporosis in
case of long-term high dose glucocorticoid use.
From November 2013 to September 2014, consecutive
postmenopausal women with RA and > 45 years of age
were recruited for the study at the Department of
Rheumatology, University of Bern, Switzerland. They ful-
filled the American College of Rheumatology criteria for
RA [15]. Data on disease duration, modified disease
activity score (DAS) including 28 joints [16], and therapy
with bisphosphonate and glucocorticoids were extracted.
Decision on use of BP had been made earlier by the
treating rheumatologist, general practitioner or expert in
osteoporosis according to the guidelines of the IOF,
ACR and ASBMR [17–19].
Exclusion criteria were as follows: hyperparathyroidism,
substance abuse (alcohol), hepatitis, HIV, malignancies,
neuropathies, previous or present use of parathyroid hor-
mone, anabolic steroid or growth hormone within 6 months
before trial entry, currently under hormone replacement
therapy, anabolic osteoporosis treatment, and creatinine
clearance <30 ml/min at baseline.
vBMD and geometry of the femur as well as thigh
muscle CSA were measured using pQCT. Measurements
of the femur are described in detail elsewhere [20, 21].
In short, pQCT measurements were performed at the
non-dominant leg (usually on the contralateral side of
the non-dominant hand) using the Stratec XCT300
scanner (Stratec, Germany). A scout view was performed
at the distal femur end. On the scout view, a reference
line was placed at the distal end of the respective bone.
Scans of the femoral diaphysis were taken at 33 % prox-
imal to the reference line. Each scan was acquired at a
slice thickness of 2 mm. Voxel size was 0.3 mm edge
length with a scanning speed of 15 mm/s at the femur.
Image processing and calculation of the various bone
parameters were performed automatically using the
manufacturer’s software package (version 5.5D). Cortical
bone properties were assessed at the diaphyseal sites
(33 %) using the default threshold value of 710 mg/cm3.
The following parameters were assessed at the diaphy-
seal site: total bone CSA (including medullary CSA),
cortical CSA (excluding medullary CSA), medullary CSA
(total CSA minus cortical CSA), and cortical volumetric
BMD (mg/cm3). Assuming the bone shaft to be cylin-
drical, cortical thickness was calculated from total CSA,
which included the bone marrow, and cortical CSA of
the diaphyseal scans. The polar bone stress–strain index
(SSI; in mm3) is a measure of diaphyseal bone resistance
to bending and torsion [22–24] and can be used as a
surrogate for bone strength [24, 25]. It was derived from
the diaphyseal scans, which were also used to quantify
muscle CSA of the thigh by measuring total leg CSA
and subtracting CSAs of bone and fat. Analogous to the
metacarpal index, we calculated a femoral index [26].
IBM SPSS Statistics 21 was used for statistical evalua-
tions. The significance level of the tests was set at 5 %. Pa-
tient characteristics and outcomes were compared between
the groups with non-parametric Mann–Whitney U tests.
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Multivariable linear regression was used to adjust the ana-
lysis for cortical thickness, cortical CSA, femoral index,
and polar SSI for possible confounders such as age, time
since menopause, disease duration, and muscle area. Nor-
mality of the residuals was checked by p-p-plots.
Results
Between 2011 and 2014, 94 consecutive RA patients
were invited to participate in the study; a total of 34
were excluded from the study as follows: premenopausal
state at age > 45 (n = 13), malignoma (n = 5), ongoing
hormone replacement therapy (n = 6), inadequate RA
diagnosis (n = 2), insufficient scan quality (n = 2), thyroid
disorders (n = 3), hepatitis (n = 1), neuropathy (n = 1) or
osteoanabolic therapy with PTH (n = 1).
Thus, 60 patients were included in our analysis; 20 pa-
tients were under treatment with BP, while 40 patients were
BP-naïve. Seven patients had euthyroid hypothyroidism
with substitution therapy. Patient characteristics of the two
groups are shown in Table 1.
To compare disease activity between the groups,
DAS28 score was analyzed if available in the patients’ re-
cords. DAS28 score overall was low (median 2.9) and
was 7.0 % lower in the BP group (p = 0.537). Ninety
percent in the BP group were on disease-modifying anti-
rheumatic drug (DMARD) with 40 % being on metho-
trexate (MTX), and 55 % on a biological. In the BP-naïve
group, 85 % were on a DMARD with 50 % being on
MTX, while 37.5 % were treated with a biological. In the
BP group, the median duration of BP therapy was
1095 days (mean: 1171 days, 95 % CI 843–1499); in half
of the patients bisphosphonates were orally adminis-
tered. At the time when bone properties were measured,
in the BP group, 50 % were receiving GC therapy with
an average dose of 2.28 mg/d; in the BP-naïve group,
47 % were receiving GC therapy with an average dose of
2.00 mg/d (p > 0.05). However, data on long-term GC
use and dosing were too meager to be used for further
analysis. 25-OH-vitamin D3 levels were between 50-
90 nmol/l, in the BP group with 85 % of the patients re-
ceiving vitamin D supplementation compared to 62.5 %
in the BP-naïve group. Total calcium intake was ap-
proximately 1000 mg/d in both groups; calcium was
supplemented in 60 % of the patients of the BP group as
against 55 % in BP-naïve group.
In the crude analysis, median cortical CSA was 5.3 %
lower (p = 0.043) in the BP group. Similar pattern was
found for median cortical thickness and the polar bone
stress–strain index (4.8 %, p = 0.076 and 13.7 %, p = 0.082
respectively; Table 2).
In order to compare the individual ratio of the CSA of
femoral bone to cortical thickness, we calculated the
relation of medullary CSA to total femoral bone CSA as
well as the femoral index. We found no difference
between the relation of medullary CSA to total femoral
bone CSA and femoral index between the two groups
(5.1 %, p = 0.113 and 3.1 %, p = 0.227 respectively;
Table 2). In order to control for the influence of other
factors, linear regression models were fitted including
potential confounders identified in the crude group
comparison (age, time since menopause, duration of RA
and muscle CSA). Cortical CSA, cortical thickness, fem-
oral index and polar SSI were set as outcomes (Table 3).
No multivariate regression model showed a significant
influence of BP therapy on bone geometry and density
of the femoral diaphysis at 33 %. Polar SSI at 33 % of
femoral diaphysis was not associated with any of the
explanatory variables (Table 3).
Discussion
In this prospective cross-sectional study, we evaluated
bone geometry, density and bone strength of the femoral
diaphysis at 33 % in 20 postmenopausal RA patients
treated with BP, comparing them with a control group of
40 postmenopausal BP-naïve RA patients. Measurements
were performed using pQCT. We found the cortical CSA
of femoral bone to be lower in BP-treated than in BP-
naïve RA patients (p = 0.043). Cortical thickness tended to
be lower (p = 0.076), medullary cavity, total femoral shaft
CSA, cortical vBMD, and polar bone SSI were not signifi-
cantly different between the groups. In a regression ana-
lysis, muscle cross-sectional area around the proximal
Table 1 Patient characteristics
BP-naïve group BP group
N Median Mean 95 %-CI of mean N Median Mean 95 %-CI of mean p-value
Age (years) 40 59.5 61.9 59.14-64.66 20 67.5 66.2 62.2-70.3 0.044
Height (cm) 39 163.0 164.0 161.7-166.3 20 160.5 160.7 157.3-164.1 0.159
Weight (kg) 38 70.0 71.61 67.2-76.0 20 69.5 68.6 63.3-74.2 0.584
Muscle area at 33 % of femur (mm2) 40 6392.4 6381.7 6055.5-6708.0 20 5291.2 5632.0 5094.2-6169.9 0.013
Age at menopause (yrs) 38 50.00 48.47 46.28-50.67 19 48.0 47.3 44.32-50.31 0.329
Time since menopause (yrs) 38 14.00 15.03 11.99-18.07 19 21.0 20.8 15.65-25.93 0.045
Duration of RA (yrs) 39 11.00 13.67 10.74-16.59 17 15.0 21.1 14.32-27.92 0.040
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thigh, age and time since menopause were factors signifi-
cantly determining cortical thickness, cortical CSA and
femoral index. No regression model showed a significant
influence of BP therapy on bone geometry and density of
the femoral diaphysis at 33 %.
To our knowledge, this is the first prospective cross-
sectional study comparing femoral bone geometry in
postmenopausal RA patients treated with BP and BP-
naïve postmenopausal RA patients. So far, only a few
studies have investigated bone shaft geometry in RA pa-
tients [2, 6, 12, 27–29]. Recently, in a prospective study,
we evaluated bone geometry and density at the third
metacarpal bone, the tibia and the radius by means of
pQCT scans. We found RA patients to have significantly
thinner cortices, whereas total CSA of the outer meta-
carpal bone shaft was increased as compared to healthy
controls [2]. In that study, we found age-associated cor-
tical bone loss in the metacarpal diaphysis, but the de-
crease in cortical thickness and increase in total CSA in
RA patients were even more pronounced. We attributed
these findings to inflammation-enhanced ageing process
[29]. In the present study, we found femoral cortical
area, thickness and femoral index to decrease with time
since menopause. Such age-associated changes in bone
geometry have been attributed to estrogen deficiency-
accelerated endocortical resorption with diminished
periosteal apposition [30]. Periosteal apposition is con-
sidered as a compensatory mechanism to counterbal-
ance buckling susceptibility, or as a coupling process
between inflammation-induced endosteal osteoclasto-
genesis and periosteal osteoblastogenesis. Since both
mechanisms are supposed to act at the same time,
changes can be designated as an “inflammatory drift”
[7, 29]. In both our previous studies, however, women
treated with BP were excluded. Thus, the effects of BP
on bone shaft geometry and vBMD in RA patients are
not well described.
When investigating the effect of BP therapy on femoral
bone, we found cortical CSA to be significantly de-
creased in patients with BP treatment while cortical
thickness, medullary cavity and femoral bone CSA were
similar between the groups. These observations leave the
possibility that BP treatment may not fully inhibit
inflammation-driven endosteal resorption in RA pa-
tients. Possible explanations for a lack of effect of BP on
bone shaft geometry are the site specificity of BP, since
the effect of BP is more likely to be seen in the trabecu-
lar bone [31], the difficulty to measure an effect of any
therapy on bone shaft geometry [8], and the reduced
effectiveness of BP in a low bone turnover state [32],
particularly in patients on small GC dose and low
disease activity, as in our study.
Our results are in agreement with those of Tournis et al.
who evaluated tibial bone geometry in 65 postmenopausal
osteoporotic RA patients treated with BP comparing it to
that in women with primary osteoporosis [12]. At 38 %
(cortical site), cortical CSA, and thickness were significantly
lower in the RA group, whereas vBMD was comparable.
Table 2 Outcomes, depicted as median, mean, and 95 % CI of the mean. (not adjusted for age, muscle area, time since menopause,
and duration of RA)
BP-naïve group BP group
N Median Mean 95 %-CI of mean N Median Mean 95 %-CI of mean p-value
Cortical CSA (mm2) at 33 % of femur 40 314.43 323.22 308.72-337.73 20 298.61 296.43 284.70-308.17 0.043
Cortical thickness in mm at 33 % of the femur 40 4.209 4.285 4.054-4.517 20 4.017 3.886 3.597-4.174 0.076
Medullary CSA (mm2) at 33 % of femur 40 180.40 191.66 172.82-210.49 20 196.68 227.65 177.84-277.45 0.466
Medullary CSA in relation to total CSA (%) 40 29.47 29.62 27.48-31.77 20 31.06 33.71 29.49-37.92 0.113
Cortical vBMD (mg/cm3) at 33 % of femur 40 1061.86 1062.03 1046.9-1077.1 20 1067.86 1036.03 994.02-1078.05 0.562
Total bone CSA (mm2) at 33 % of femur 40 623.11 639.91 613.87-665.94 20 643.31 649.58 586.36-712.81 0.925
Femoral index (%) 40 29.791 30.279 28.406-32.12 20 28.897 27.769 24.672-30.865 0.227
Polar SSI (mm3) 40 2640.840 2590.723 2411.798- 2769.648 20 2321.920 2277.980 2008.614- 2547.347 0.082
Table 3 Summary of linear regression models for cortical thickness, cortical CSA, and femoral index
Cortical CSA Cortical thickness Femoral index Pol SSI
β p-value β p-value β p-value β p-value
Age 0.570 0.004 0.596 0.003 0.505 0.015 −0.066 0.763
Time since menopause −0.414 0.032 −0.541 0.006 −0.525 0.010 0.121 0.577
Duration of RA 0.029 0.828 −0.079 0.550 −0.122 0.384 −0.090 0.558
Muscle CSA 0.398 0.004 0.375 0.006 0.305 0.032 0.122 0.424
BP −0.251 0.071 −0.189 0.170 −0.115 0.425 −0.235 0.140
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Since periosteal circumference was comparable and endos-
teal circumference significantly higher, these results may be
interpreted as ongoing endosteal trabecularisation and loss
of cortical bone despite BP therapy. Concordant results
were reported by Chen et al., who compared long-term BP
users with therapy-naïve controls. They found BP users to
have significantly thinner cortices than controls [33]. On
the other hand, Zanchetta et al. compared the bone micro-
architecture of distal radius and tibia in patients under BP
treatment, treatment-naïve patients and patients with AFF
and found no difference between the groups in cortical area
or density [34]. Comparable bone resistance to bending and
torsion calculated as polar SSI at 33 % of femoral diaphysis
in our study may support the findings of Zanchetta et al. at
radius and tibia.
There is still controversy on whether bisphosphonates
change cortical bone geometry. In order to assess the ef-
fects of BP on bone geometry, we included muscle CSA
around the proximal thigh, particularly since muscle
force and loading have a high impact on bone adaptation
[35]. When adjusted for determining factors, we found
cortical thickness, cortical CSA and femoral index to
highly correlate with muscle CSA.
In our study, muscle CSA at 33 % of femur was 13 %
lower in patients under BP treatment compared to BP-
naïve patients. These results are in agreement with recently
published data by Uchiyama et al. who reported that BP
therapy was associated with lower skeletal muscle mass at
the proximal femur [36]. Chen et al. suggest that the im-
paired muscle mass in BP users may be due to comorbidi-
ties such as arthritis, asthma and osteoporosis, which have
been reported to be associated with impaired muscle mass
and strength [37]. Another factor is long-term GC therapy,
the duration and dosage of which is most likely higher in
BP users and causes wasting of proximal skeletal muscles
[38]. In addition, alendronate has been shown in vitro to
attenuate muscle regeneration capacity by preventing mi-
gration, proliferation and differentiation of undifferentiated
human myogenic cells [39]. Since in our study, BP users
had lower muscle CSA at 33 % of femur, we assume they
are physically less active, generally in a poorer state of
health and possibly have more comorbidities. Geometric
differences of the femoral diaphysis that lead to AFF are
therefore more likely to be caused by factors other than BP
therapy and likely to be associated with altered unbalanced
tensile strain pattern in the lateral femoral shaft during
walking [40], an underlying hip geometry [41, 42], or due to
a larger tibio-femoral angle [43], which then may place
extra demands on the diaphyseal bone against resistance to
bending and torsion.
Strengths
The strength of this study is the method and site of
measurement. Firstly, by measuring with pQCT, we were
able to measure bone geometry such as total and cortical
area, periosteal and endosteal circumference and cortical
vBMD. Measurement of muscle area, a surrogate of
muscle force, assesses differences in bone geometry in
relationship to muscle force. Secondly, by choosing the
site of femoral diaphysis, we were in close vicinity of the
site where changes in bone density and geometry were
measured in patients with of atypical femoral fractures.
Limitations
The main limitation of our study is the small sample
size. Since therapy was given only to patients with osteo-
porosis or increased fracture-risk, differences between
the groups are likely to be confounded by this (potential)
imbalance and it is difficult to distinguish the effect of
the therapy from these confounding factors. Longitu-
dinal studies are needed to further clarify the effect of
BP on changes of muscle cross-sectional area, bone
geometry, density and bone strength.
Conclusion
The results of this study demonstrate that differences in
bone femoral geometry between menopausal RA patients
under long-term BP therapy and those not receiving BP
are dependent on muscle area around the proximal thigh,
age and time since menopause. No regression model
showed BP therapy to have any significant impact on bone
geometry, density or bone strength of the femoral diaphysis
at 33 %.
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